Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Services. Health policy experts have said a second Trump term could allow Kennedy to elevate anti-vaccine rhetoric.
Why vaccine stocks tumbled after Trump chose RFK Jr for US health secretary
The selection of vaccine sceptic Robert F Kennedy Jr by US President-elect Donald Trump to head the Department of Health and Human Services has sparked a market shock, with stocks of leading vaccine makers,
Trump Picks Vaccine Skeptic Robert F. Kennedy Jr. to Lead Health & Human Services
In a move guaranteed to alarm many, President-elect Donald Trump has chosen Robert F. Kennedy Jr., a vocal opponent of vaccines and other tenets of mainstream health care, to head the massive U.S. Department of Health and Human Services (HHS).
Trump taps Robert F. Kennedy Jr., vaccine skeptic, to lead health department
The nearly $2 trillion agency administers health-insurance programs for millions of Americans, approves medications and oversees vaccine safety.
Vaccine makers fall after Trump nominates RFK to head HHS
BioNTech (BNTX), Pfizer (PFE), Novavax (NVAX), Vaxcyte (PCVX) and GSK (GSK) moved lower at the end of the trading day following reports that President-elect Donald Trump Donald Trump would nominate noted vaccine skeptic Robert F.
Trump Selects RFK Jr. for Health Secretary; Vaccine Stocks Fall
President-elect Donald Trump said he’s tapping Robert F. Kennedy Jr., to run the Department of Health and Human Services, a move that would elevate a prominent vaccine skeptic and pharmaceutical industry critic to a top role on federal health policy.
LIVE
Trump picks vaccine sceptic RFK Jr for health secretary
Donald Trump says Kennedy will help protect Americans from "harmful chemicals" and "make America healthy again".
Vaccine maker stocks tumble after Trump picks RFK Jr. for health secretary
Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F. Kennedy Jr. to be the next secretary of the Department of Health and Human Services.
BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain ...
GlobalData on MSN22h
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Investor's Business Daily on MSN12h
BioNTech Stock Got A IBD RS Rating Lift
How Much Money To Invest Now. Is BioNTech Stock A Buy? BioNTech stock is building a consolidation with a 131.49 buy point.
The Analyst Landscape: 17 Takes On BioNTech
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
FierceBiotech2d
BioNTech pays $800M to take control of potential Keytruda killer
BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
STAT1d
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
AOL1d
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
BioPharma Dive1d
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
Strategic Acquisition and Oncology Focus Justify BioNTech’s Buy Rating
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...